Display options
Cite
Borregales LD, Adibi M, Thomas AZ, et al. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2015;8(2):130-41doi: 10.1177/1756287215612962.
Borregales, L. D., Adibi, M., Thomas, A. Z., Wood, C. G., & Karam, J. A. (2016). The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Therapeutic advances in urology, 8(2), 130-41. https://doi.org/10.1177/1756287215612962
Borregales, Leonardo D, et al. "The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma." Therapeutic advances in urology vol. 8,2 (2016): 130-41. doi: https://doi.org/10.1177/1756287215612962
Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016 Apr;8(2):130-41. doi: 10.1177/1756287215612962. Epub 2015 Nov 20. PMID: 27034725; PMCID: PMC4772353.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Urol. 2016 Apr;8(2):130-41. doi: 10.1177/1756287215612962. Epub 2015 Nov 20.

The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma.

Therapeutic advances in urology

Leonardo D Borregales, Mehrad Adibi, Arun Z Thomas, Christopher G Wood, Jose A Karam

Affiliations

  1. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  2. Department of Urology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1373, Houston, TX 77030, USA.

PMID: 27034725 PMCID: PMC4772353 DOI: 10.1177/1756287215612962

Abstract

In the past decade, the armamentarium of targeted therapy agents for the treatment of metastatic renal cell carcinoma (RCC) has significantly increased. Improvements in response rates and survival, with more manageable side effects compared with interleukin 2/interferon immunotherapy, have been reported with the use of targeted therapy agents, including vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib, axitinib), mammalian target of rapamycin (mTOR) inhibitors (everolimus and temsirolimus) and VEGF receptor antibodies (bevacizumab). Current guidelines reflect these new therapeutic approaches with treatments based on risk category, histology and line of therapy in the metastatic setting. However, while radical nephrectomy remains the standard of care for locally advanced RCC, the migration and use of these agents from salvage to the neoadjuvant setting for large unresectable masses, high-level venous tumor thrombus involvement, and patients with imperative indications for nephron sparing has been increasingly described in the literature. Several trials have recently been published and some are still recruiting patients in the neoadjuvant setting. While the results of these trials will inform and guide the use of these agents in the neoadjuvant setting, there still remains a considerable lack of consensus in the literature regarding the effectiveness, safety and clinical utility of neoadjuvant therapy. The goal of this review is to shed light on the current body of evidence with regards to the use of neoadjuvant treatments in the setting of locally advanced RCC.

Keywords: locally advanced; neoadjuvant; nephrectomy; preoperative; presurgical; renal cell carcinoma; targeted therapy

References

  1. Cancer. 2009 May 15;115(10 Suppl):2355-60 - PubMed
  2. Int J Urol. 2013 Jun;20(6):637-9 - PubMed
  3. Curr Opin Urol. 2011 Sep;21(5):368-75 - PubMed
  4. Urology. 2010 May;75(5):1108-13.e1 - PubMed
  5. World J Urol. 2014 Feb;32(1):245-8 - PubMed
  6. N Engl J Med. 2004 Jun 3;350(23 ):2335-42 - PubMed
  7. Am J Kidney Dis. 2014 Jan;63(1 Suppl):A7 - PubMed
  8. J Clin Oncol. 2009 Sep 1;27(25):4076-81 - PubMed
  9. J Urol. 2009 Feb;181(2):518-23; discussion 523 - PubMed
  10. J Urol. 2010 Sep;184(3):859-64 - PubMed
  11. BJU Int. 2010 Nov;106(9):1270-6 - PubMed
  12. J Urol. 2015 Aug;194(2):297-303 - PubMed
  13. Ann Surg Oncol. 2011 Mar;18(3):733-7 - PubMed
  14. Eur Urol. 2011 Jun;59(6):912-8 - PubMed
  15. J Urol. 2012 May;187(5):1548-54 - PubMed
  16. Urol Oncol. 2013 Oct;31(7):1316-20 - PubMed
  17. Eur Urol. 2014 Nov;66(5):874-80 - PubMed
  18. Eur Urol. 2011 Nov;60(5):964-71 - PubMed
  19. Acta Oncol. 2010 May;49(4):520-3 - PubMed
  20. J Cancer Res Clin Oncol. 2014 Oct;140(10 ):1751-8 - PubMed
  21. Kidney Int. 2011 Sep;80(6):572-86 - PubMed
  22. Anticancer Res. 2012 May;32(5):1729-35 - PubMed
  23. World J Urol. 2014 Feb;32(1):109-14 - PubMed
  24. Urol Int. 2008;80(4):451-3 - PubMed
  25. Eur Urol. 2011 Sep;60(3):448-54 - PubMed
  26. Clin Cancer Res. 2012 Jul 15;18(14 ):3961-71 - PubMed
  27. Jpn J Clin Oncol. 2014 Apr;44(4):370-3 - PubMed
  28. Expert Rev Anticancer Ther. 2012 Dec;12(12):1559-69 - PubMed
  29. Clin Cancer Res. 2008 Apr 15;14 (8):2431-6 - PubMed
  30. Eur Urol. 2014 Sep;66(3):584-92 - PubMed
  31. Nat Rev Urol. 2014 May;11(5):254-5 - PubMed
  32. J Clin Oncol. 2010 Mar 20;28(9):1502-7 - PubMed
  33. BJU Int. 2016 Apr;117(4):629-35 - PubMed
  34. PLoS One. 2015 Feb 03;10(2):e0115896 - PubMed
  35. World J Urol. 2009 Aug;27(4):533-9 - PubMed
  36. N Engl J Med. 2004 Sep 23;351(13):1296-305 - PubMed
  37. BJU Int. 2011 Mar;107(5):724-8 - PubMed
  38. Nat Rev Urol. 2009 Jun;6(6):338-43 - PubMed
  39. Jpn J Clin Oncol. 2010 Dec;40(12 ):1173-9 - PubMed
  40. Ann Oncol. 2011 May;22(5):1041-7 - PubMed
  41. BJU Int. 2008 Sep;102(6):692-6 - PubMed
  42. Eur Urol. 2009 Jun;55(6):1477-80 - PubMed

Publication Types